Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm
Mandate

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

June 25, 2018 Capital Markets and Public M&A

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.

The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
 
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. 
 
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.

Related

Vinge has advised Viva Wine Group AB in connection with the acquisition of the Norwegian beverage company Alpha Brands

 Vinge has advised Viva Wine Group AB in connection with the acquisition of 60 percent of the shares in the Norwegian beverage company Alpha Brands, for an initial cash purchase price of MNOK 33, with a possible earn-out based on the company's performance development.
February 09, 2026

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Newbow Aerospace Limited

 Newbow Aerospace is a UK-based market-leading manufacturer and supplier of ground support equipment (GSE) used for the safe and efficient maintenance of aircraft.
February 09, 2026

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026